Lack of regression of atherosclerotic lesions in phytosterol-treated apo E-deficient mice. 1999

M H Moghadasian, and D V Godin, and B M McManus, and J J Frohlich
Department of Pathology and Laboratory Medicine, St. Paul's Hospital and University of British Columbia, Vancouver, Canada.

We evaluated the effects of a phytosterol mixture (FCP-3PI) on the regression of atherosclerotic lesions in male apo E-deficient mice. Atherosclerosis was induced in fifteen mice by a "Western-type" diet containing 9% (w/w) fat and 0.15% (w/w) cholesterol over a period of 18 weeks (Induction phase). Then, two mice were used to evaluate the development of atherosclerosis, and the rest was divided into the control (n=6) and treated (n=7) groups. The control group was fed mouse chow (4.5% w/w fat) and the treated group fed the same chow supplemented with 2% (w/w) FCP-3PI for an additional 25 weeks (Regression phase). The mice developed severe hypercholesterolemia and advanced atherosclerotic lesions over the induction phase. During the first 6 weeks of regression phase, plasma cholesterol concentrations decreased at a similar rate (35%) in both groups of control and phytosterol-treated mice. Although evidence of lesion regression was not observed in either group of mice, the treated group had slightly smaller lesion size than the controls. During the induction phase, each mouse developed atherosclerotic lesions averaging 0.025 mm2 per week. However, during the regression phase, this was decreased to approximately one fifth and one third in the treated and control groups, respectively. Thus, compared to the end of the induction phase, the control group had a 40% increase in the lesion size, while this increase was only 28% in the treated animals. In conclusion, our previous findings along with a small decrease in the atherosclerotic lesion size observed in the treated group in the present study suggest that FCP-3PI treatment may slow the development of atherosclerotic lesions in apo E-deficient mice; however, a longer regression period may yield a greater benefit.

UI MeSH Term Description Entries
D008297 Male Males
D010840 Phytosterols A class of organic compounds known as sterols or STEROIDS derived from plants. Plant Sterols,Phytosteroid,Phytosteroids,Phytosterol,Plant Steroid,Plant Steroids,Plant Sterol,Steroid, Plant,Steroids, Plant,Sterol, Plant,Sterols, Plant
D001835 Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms. Body Weights,Weight, Body,Weights, Body
D002784 Cholesterol The principal sterol of all higher animals, distributed in body tissues, especially the brain and spinal cord, and in animal fats and oils. Epicholesterol
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001057 Apolipoproteins E A class of protein components which can be found in several lipoproteins including HIGH-DENSITY LIPOPROTEINS; VERY-LOW-DENSITY LIPOPROTEINS; and CHYLOMICRONS. Synthesized in most organs, Apo E is important in the global transport of lipids and cholesterol throughout the body. Apo E is also a ligand for LDL receptors (RECEPTORS, LDL) that mediates the binding, internalization, and catabolism of lipoprotein particles in cells. There are several allelic isoforms (such as E2, E3, and E4). Deficiency or defects in Apo E are causes of HYPERLIPOPROTEINEMIA TYPE III. Apo-E,Apo E,Apo E Isoproteins,ApoE,Apolipoprotein E Isoproteins,Apoprotein (E),Apoproteins E,Isoproteins, Apo E,Isoproteins, Apolipoprotein E
D001161 Arteriosclerosis Thickening and loss of elasticity of the walls of ARTERIES of all sizes. There are many forms classified by the types of lesions and arteries involved, such as ATHEROSCLEROSIS with fatty lesions in the ARTERIAL INTIMA of medium and large muscular arteries. Arterioscleroses
D014973 Xanthomatosis A condition marked by the development of widespread xanthomas, yellow tumor-like structures filled with lipid deposits. Xanthomas can be found in a variety of tissues including the SKIN; TENDONS; joints of KNEES and ELBOWS. Xanthomatosis is associated with disturbance of LIPID METABOLISM and formation of FOAM CELLS. Xanthoma,Xanthomas,Xanthomatoses
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus

Related Publications

M H Moghadasian, and D V Godin, and B M McManus, and J J Frohlich
September 2006, Journal of biochemistry,
M H Moghadasian, and D V Godin, and B M McManus, and J J Frohlich
August 2008, The Journal of nutritional biochemistry,
M H Moghadasian, and D V Godin, and B M McManus, and J J Frohlich
December 2011, The Journal of surgical research,
M H Moghadasian, and D V Godin, and B M McManus, and J J Frohlich
June 2009, Atherosclerosis,
M H Moghadasian, and D V Godin, and B M McManus, and J J Frohlich
August 2008, Atherosclerosis,
M H Moghadasian, and D V Godin, and B M McManus, and J J Frohlich
October 2001, Clinical and experimental pharmacology & physiology,
M H Moghadasian, and D V Godin, and B M McManus, and J J Frohlich
September 2004, Atherosclerosis,
M H Moghadasian, and D V Godin, and B M McManus, and J J Frohlich
November 2013, International journal of cardiology,
M H Moghadasian, and D V Godin, and B M McManus, and J J Frohlich
April 2011, Prostaglandins & other lipid mediators,
Copied contents to your clipboard!